Heterotopic ossification after hip arthroplasty: a randomized double-blind multicenter study tenoxicam in 147 hips

Area of Science:

• Orthopedic Surgery
• Pharmacology
• Medical Imaging

Background:

• Heterotopic ossification (HO) is a common complication following cemented total hip arthroplasty (THA).
• HO can lead to pain, stiffness, and impaired joint function, necessitating further medical intervention.
• Current prophylactic strategies for HO post-THA have varying efficacy and side effect profiles.

Purpose of the Study:

• To evaluate the efficacy of tenoxicam in preventing heterotopic ossification after cemented total hip arthroplasty.
• To compare the effects of different doses of tenoxicam (20 mg vs. 40 mg) and placebo.
• To assess the effectiveness of tenoxicam against a morphine control group.

Main Methods:

• A randomized controlled trial involving 147 patients scheduled for cemented THA.
• Patients were assigned to receive either tenoxicam (20 mg or 40 mg) or placebo for 5 days, or morphine followed by placebo.
• Follow-up was conducted for 1 year to assess the incidence of heterotopic ossification.

Main Results:

• Significantly fewer patients developed heterotopic ossification in the tenoxicam groups compared to placebo and morphine groups.
• No significant difference in HO incidence was observed between the 20 mg and 40 mg tenoxicam groups.
• Tenoxicam demonstrated a clear benefit in reducing HO formation post-cemented THA.

Conclusions:

• Postoperative administration of tenoxicam 20 mg for 5 days is effective in reducing heterotopic ossification after cemented total hip arthroplasty.
• Tenoxicam offers a promising therapeutic option for preventing HO complications in THA patients.
• Further research may explore optimal dosing and long-term outcomes of tenoxicam for HO prevention.